Table 2. Change of clinical symptoms after LI-ESWT.
| Sample, weeks | Timepoint | ||||
|---|---|---|---|---|---|
| Baseline | Week 1 | Week 2 | Week 4 | Week 12 | |
| Pain score (items 1–4) | 12.43±5.40 | 10.71±4.86 | 9.86 ±4.05 | 5.43±3.67a | 7.43±4.18a |
| Urinary score (items 5–6) | 4.57±3.76 | 4.14±3.3 | 3.71±3.27 | 2.86±2.51 | 3.43±3.13 |
| QoL (items 7–9) | 9.14±2.38 | 9±3.09 | 8.71±3.27 | 7.86±3.57 | 8.71±3.17 |
| NIH-CPSI (items 1–9) | 26.14±9.26 | 23.86±8.51 | 22.29±7.46 | 16.14±6.09a | 19.57±7.31a |
| VAS | 6.14±2.86 | 5.29±2.92 | 4.86±2.25 | 3±1.84a | 4±1.66a |
a, statistically significant difference compared with the first values between corresponding groups. VAS, Visual Analog Scale; QoL, quality of life; NIH-CPSI, National Institutes of Health Chronic Prostatitis Symptom Index; LI-ESWT, low-intensity extracorporeal shock wave therapy.